Vancouver April 15, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy Therapeutics” or the “Company”) is pleased to announce that today it has filed its annual financial statements in respect of its year ended September 30, 2023, its management discussion and analysis relating to its annual financial statements, and the CEO and CFO certifications (collectively, the “Required Documents“). The Filings are available on SEDAR+ as well as the CSE website.
As previously announced, the Company is under a voluntary management cease trade order (“MCTO“) for failure to file its annual financials and the required documents and it will remain in default until it completes the filing of its Q1 Interim Financial statements for the period ended December 31, 2023 along with the management discussion and analysis, and the interim CEO and CFO certifications.
The Company intends to satisfy the provisions of the alternative information guidelines in accordance with National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“) by issuing default status reports in the form of news releases until the situation is satisfactorily rectified.
Xtacy confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments other than the posting of the annual financials today.
About Xtacy Therapeutics Corp.:
Xtacy Therapeutics Corp. is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies.
For further information visit websites:
www.xtacytherapeutics.com
Or Contact Meris Kott CEO 604.484.0355 or email to [email protected]
Further information about the Company is available on www.SEDARplus.ca under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
